MAPT and Alzheimer disease: Those with late‐life depression and cognitive impairment had higher Aβ42 CSF levels and lower t‐tau and p‐tau CSF levels compared with those with AD without depression, suggesting that analysis of fluid biomarkers may aid in the diagnosis of AD versus late‐life depression.